Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology].

Rabenstein T, Fromm MF, Zolk O.

Z Gastroenterol. 2011 Feb;49(2):211-24. doi: 10.1055/s-0029-1245705. Epub 2011 Jan 11. Review. German.

PMID:
21225568
2.

Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.

Cottreau J, Baker SF, DuPont HL, Garey KW.

Expert Rev Anti Infect Ther. 2010 Jul;8(7):747-60. doi: 10.1586/eri.10.58.

PMID:
20586560
3.

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.

Gerard L, Garey KW, DuPont HL.

Expert Rev Anti Infect Ther. 2005 Apr;3(2):201-11. Review.

PMID:
15918778
4.

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Koo HL, DuPont HL.

Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d. Review.

5.

Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.

DuPont HL.

Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:1-2. doi: 10.1111/apt.13406.

6.

Use of rifaximin in gastrointestinal and liver diseases.

Shayto RH, Abou Mrad R, Sharara AI.

World J Gastroenterol. 2016 Aug 7;22(29):6638-51. doi: 10.3748/wjg.v22.i29.6638. Review.

7.

Rifaximin: a review of its use in the management of traveller's diarrhoea.

Robins GW, Wellington K.

Drugs. 2005;65(12):1697-713. Review.

PMID:
16060706
8.

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

Scarpignato C, Pelosini I.

Chemotherapy. 2005;51 Suppl 1:36-66. Review.

PMID:
15855748
9.

New trends in non-absorbable antibiotics in gastrointestinal disease.

Di Febo G, Calabrese C, Matassoni F.

Ital J Gastroenterol. 1992 Nov-Dec;24(9 Suppl 2):10-3. Review.

PMID:
1486193
10.

Biologic properties and clinical uses of rifaximin.

DuPont HL.

Expert Opin Pharmacother. 2011 Feb;12(2):293-302. doi: 10.1517/14656566.2011.546347. Review.

PMID:
21226639
11.

Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.

Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW.

Am J Med Sci. 2007 May;333(5):266-70.

PMID:
17505166
12.

Rifaximin pharmacology and clinical implications.

Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A.

Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):675-82. doi: 10.1517/17425250902973695. Review.

PMID:
19442033
13.

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR.

Aliment Pharmacol Ther. 2000 May;14(5):551-6.

14.

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A.

Aliment Pharmacol Ther. 2005 Jul 1;22(1):31-5.

15.

Rifaximin for the treatment of irritable bowel syndrome.

Cremonini F, Lembo A.

Expert Opin Pharmacother. 2012 Feb;13(3):433-40. doi: 10.1517/14656566.2012.651458. Epub 2012 Jan 18. Review.

PMID:
22251066
16.

Rifaximin: beyond the traditional antibiotic activity.

Calanni F, Renzulli C, Barbanti M, Viscomi GC.

J Antibiot (Tokyo). 2014 Sep;67(9):667-70. doi: 10.1038/ja.2014.106. Epub 2014 Aug 6. Review.

PMID:
25095806
17.

Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.

Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A.

Expert Opin Drug Saf. 2016 Jul;15(7):983-91. doi: 10.1080/14740338.2016.1186639. Epub 2016 May 23. Review.

PMID:
27149541
18.

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.

Furnari M, Parodi A, Gemignani L, Giannini EG, Marenco S, Savarino E, Assandri L, Fazio V, Bonfanti D, Inferrera S, Savarino V.

Aliment Pharmacol Ther. 2010 Oct;32(8):1000-6. doi: 10.1111/j.1365-2036.2010.04436.x. Epub 2010 Aug 18.

19.

[Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].

Gasztonyi B, Hunyady B.

Orv Hetil. 2004 Oct 24;145(43):2177-81. Review. Hungarian.

PMID:
15575494
20.

Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.

Di Stefano M, Corazza GR.

Chemotherapy. 2005;51 Suppl 1:103-9. Review.

PMID:
15855754

Supplemental Content

Support Center